云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

交易中 09-04 10:58:12

32.960

+0.480

+1.48%

最高33.600	最低32.560	成交量360.68万
今开33.420	昨收32.480	日振幅3.20%
总市值116.68亿	流通市值116.68亿	总股本3.54亿
成交额1.19亿	换手率1.02%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":32.96,"timestamp":1788490668590,"preClose":32.48,"halted":0,"volume":3606786,"delay":0,"changeRate":0.014778325123152834,"floatShares":354000000,"shares":354000000,"eps":-0.89,"marketStatus":"交易中","change":0.48,"latestTime":"09-04 10:58:12","open":33.42,"high":33.6,"low":32.56,"amount":119391885,"amplitude":0.03202,"askPrice":32.98,"askSize":2500,"bidPrice":32.96,"bidSize":15500,"shortable":3,"etf":0,"ttmEps":-0.175,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1788494400000},"marketStatusCode":2,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":32.48,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":1.335027,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1140066454","title":"里程碑医药在华获批触发200万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1140066454","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140066454?lang=zh_cn&edition=full","pubTime":"2026-09-03 23:00","pubTimestamp":1788447612,"startTime":"0","endTime":"0","summary":"9月3日（路透社）——Milestone Pharmaceuticals Inc.今日宣布，其用于治疗阵发性室上性心动过速的依曲帕米鼻喷雾剂已获得中国国家药品监督管理局的批准。此项批准具有里程碑意义，标志着依曲帕米首次在美国以外的地区获得监管许可。该公司进一步披露，NMPA的此次批准触发了云顶新耀应向Milestone Pharmaceuticals支付的200万美元里程碑付款。Milestone Pharmaceuticals表示，依照与云顶新耀的协议条款，该公司在大中华区有资格获得高达9800万美元的里程碑付款，以及最高可达18%的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01952","BK4007","MIST","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102831820","title":"云顶新耀(01952)心血管产品线迎里程碑：星必妥获NMPA批准治疗成人PSVT急性发作","url":"https://stock-news.laohu8.com/highlight/detail?id=1102831820","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102831820?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:11","pubTimestamp":1788437517,"startTime":"0","endTime":"0","summary":"2026年9月3日，云顶新耀有限公司公告称，其创新药物星必妥已获中国国家药品监督管理局批准，用于治疗成人阵发性室上性心动过速急性症状发作并转复为窦性心律。此次批准系基于两项III期临床研究数据。此前，星必妥已于2025年12月获美国食品药品监督管理局批准，成为30多年来首个且唯一获批用于成人PSVT急性症状发作治疗的创新疗法。云顶新耀表示，将继续加快创新产品商业化进程，推进星必妥在国内上市后的市场拓展工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874368","title":"云顶新耀(01952)：星必妥®用于治疗成人阵发性室上性心动过速急性症状发作转复为窦性心律的新药上市申请在中国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874368","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664874368?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:09","pubTimestamp":1788437371,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，中国国家药品监督管理局已批准星必妥的新药上市许可申请，用于治疗成人阵发性室上性心动过速急性症状发作，转复为窦性心律。此前，星必妥已于2025年12月获得美国食品药品监督管理局批准，成为30多年来首款且唯一获批用于成人PSVT急性症状发作治疗的创新疗法。作为本公司在心血管疾病领域首个获批的创新药物，星必妥进一步丰富了本公司的创新产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1583","BK1161","BK1574","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191020213","title":"异动解读｜云顶新耀盘中下跌5.19%，mRNA概念持续退潮叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1191020213","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191020213?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:09","pubTimestamp":1788142147,"startTime":"0","endTime":"0","summary":"8月31日，云顶新耀盘中下跌5.19%，报32.94港元，成交额1.08亿港元。消息面上，公司此轮下跌延续了mRNA概念情绪退潮及生物科技板块整体走弱趋势。此前受默沙东与莫德纳mRNA个性化癌症疫苗三期临床积极结果催化，云顶新耀自8月20日起累计最高涨幅曾超55%，近日前期获利盘持续回吐。同板块内，康希诺生物跌5.86%、百济神州跌4.81%、康方生物跌4.56%，行业个股普遍承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀下跌，mRNA概念持续退潮","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102983502","title":"异动解读｜云顶新耀盘中下跌5.2%，mRNA概念情绪退潮叠加板块整体走弱拖累回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1102983502","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102983502?lang=zh_cn&edition=full","pubTime":"2026-08-28 14:53","pubTimestamp":1787900030,"startTime":"0","endTime":"0","summary":"8月28日，云顶新耀盘中下跌5.2%，报34.98港元，成交额3.24亿港元。今日生物科技板块整体承压，同为mRNA概念的康希诺生物同日跌超10%，板块情绪明显降温，前期涨幅较大个股面临获利回吐压力。基本面方面，公司上半年收入11.48亿元人民币，同比增长157%，实现扭亏为盈；核心产品耐赋康销售同比增长94%。交银国际此前维持买入评级，目标价66港元，但同时下调收入预测15%至18%，提示耐赋康竞争加剧及依嘉供应紧张风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀回调，mRNA概念情绪退潮","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149905224","title":"港股直击｜创新药股股价齐扬，隔夜美股公司Moderna股价飙升14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149905224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149905224?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:39","pubTimestamp":1787708343,"startTime":"0","endTime":"0","summary":"港股创新药股股价齐扬，云顶新耀升 8%，康方生物升 7%，药明巨诺升 5%，荣昌生物升 4%。消息面上，隔夜美股生物技术公司莫德纳(Moderna)股价飙升14%，此前巴克莱上调了其目标价，且投资机构Wolfe Research也看好该公司mRNA癌症疫苗的商业潜力。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","09926","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144227564","title":"异动解读｜云顶新耀盘中上涨5.16%，mRNA肿瘤疫苗催化延续叠加中期业绩高增驱动连续走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1144227564","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144227564?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:30","pubTimestamp":1787707851,"startTime":"0","endTime":"0","summary":"8月26日，云顶新耀盘中上涨5.16%，报39.0港元，成交额2454.98万港元。该股延续近期强势表现，自8月20日莫德纳与默沙东mRNA个性化癌症疫苗III期临床阳性结果公布以来持续获得资金关注。同时，公司自研mRNA平台布局的个性化肿瘤疫苗EVM16已在AACR年会披露首次人体数据，免疫应答率近九成，现货型疫苗EVM14亦在中美两地推进I期临床。交银国际维持买入评级，目标价66港元。同板块康希诺生物同日涨超14%，mRNA概念情绪仍在延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀异动上涨，mRNA疫苗催化延续","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662786193","title":"云顶新耀午后大涨超17% 核心产品耐赋康放量带动业绩高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2662786193","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662786193?lang=zh_cn&edition=full","pubTime":"2026-08-25 13:50","pubTimestamp":1787637000,"startTime":"0","endTime":"0","summary":"模拟交易客户端云顶新耀午后涨幅持续扩大，截至发稿，股价上涨17.24%，现报36.46港元，成交额8.318亿港元。云顶新耀披露中期业绩，上半年收入人民币11.48亿元，同比增长157%；经调整利润为0.97亿元，实现扭亏为盈。核心产品耐赋康销售收入达到人民币8.89亿元，纯销同比增长94%，医院覆盖和患者规模持续扩大。中信建投则表示，云顶新耀拥有端到端mRNA技术平台，AI算法打造核心竞争力，布局个性化肿瘤疫苗EVM16和现货型疫苗EVM14。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-25/doc-inippewu5522966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01952","BK1161","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662788417","title":"港股异动 | 云顶新耀(01952.HK)再涨超9% 耐赋康放量带动业绩高增 mRNA肿瘤疫苗赛道进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662788417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662788417?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:14","pubTimestamp":1787627656,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01952","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109503028","title":"异动解读｜云顶新耀盘中上涨5.14%，mRNA癌症疫苗催化余温延续叠加券商维持买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1109503028","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109503028?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:43","pubTimestamp":1787622184,"startTime":"0","endTime":"0","summary":"8月25日，云顶新耀盘中上涨5.14%，报32.66港元，成交额1.05亿港元。此前该股受莫德纳与默沙东mRNA个性化癌症疫苗三期临床阳性结果及中期业绩大超预期双重催化，8月20日单日飙涨逾41%，随后连续两日回调累计跌超13%，近两个交易日呈现技术性修复态势。该行指出公司上半年耐赋康销售同比大增94%，重申双向BD策略，mRNA技术平台与已验证商业化基础设施有望持续兑现价值。同板块mRNA概念情绪仍有延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀上涨，mRNA疫苗催化余温延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661272296","title":"mRNA赛道迎历史性突破，云顶新耀自研价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2661272296","media":"天府财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661272296?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:28","pubTimestamp":1787581680,"startTime":"0","endTime":"0","summary":"消息公布后，Moderna股价大幅上涨，mRNA肿瘤免疫赛道随之升温。Moderna的临床突破，确立了其在mRNA肿瘤疫苗领域的先发优势，但当前这一赛道远非终局。值得注意的是，近日，云顶新耀发布了2026年中期业绩。mRNA平台作为其自主研发体系的重要支柱，有望在肿瘤免疫新时代持续释放增长动能。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-08-24/doc-inipmsvk1961020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","01952","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195318104","title":"异动解读｜云顶新耀盘中上涨5.28%，mRNA催化余温未散叠加券商维持买入评级提振反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1195318104","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195318104?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:34","pubTimestamp":1787535262,"startTime":"0","endTime":"0","summary":"8月24日，云顶新耀盘中上涨5.28%，报32.82港元，成交额1.04亿港元。此前该股受莫德纳与默沙东mRNA个性化癌症疫苗三期临床阳性结果及中期业绩大超预期双重催化，8月20日单日飙涨逾41%，随后连续两日回调累计跌幅超13%，今日出现技术性反弹。同板块康希诺生物同日涨1.15%，mRNA概念板块情绪仍有延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀强势反弹，券商维持买入评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156450526","title":"异动解读｜云顶新耀盘中下跌6.77%，前日mRNA利好大涨后资金获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1156450526","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156450526?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:31","pubTimestamp":1787275886,"startTime":"0","endTime":"0","summary":"8月21日，云顶新耀盘中下跌6.77%，报31.34港元，成交额1874.68万港元。此前一个交易日，受莫德纳与默沙东mRNA个性化癌症疫苗三期临床取得阳性结果及公司中期业绩大超预期双重催化，该股盘中一度飙升近89%，收涨41.43%。今日开盘即出现明显回落，市场资金获利了结意愿较强。同板块康希诺生物同日跌3.31%，mRNA概念股整体呈现冲高回落态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"云顶新耀冲高回落，获利资金离场","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661025531","title":"【券商聚焦】交银国际维持云顶新耀（01952）买入评级 指上半年耐赋康销售持续高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2661025531","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661025531?lang=zh_cn&edition=full","pubTime":"2026-08-21 08:53","pubTimestamp":1787273602,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，云顶新耀 1H26实现收入11.48亿元，同比大增157%，其中：1）耐赋康销售收入8.89亿元，同比+94%。2）依嘉院内销量同比增加28%，但海外CDMO供应紧张致少发货约1.5亿元。考虑到耐赋康面临竞争加剧以及依嘉的短期供应紧张，我们下调2026-28年收入预测15-18%、下调耐赋康长期峰值销售预测。我们基于DCF模型得到最新目标价66港元，高效BD执行力+已验证商业化基础设施有望持续兑现价值，维持买入评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660477197","title":"mRNA领域重大突破！创新药概念股飙升，云顶新耀飙升55%，晶泰控股、金斯瑞大涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477197","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660477197?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:17","pubTimestamp":1787192273,"startTime":"0","endTime":"0","summary":"消息面上，美国制药企业默沙东和莫德纳周三宣布，其实验性信使核糖核酸皮肤癌疫苗在最后阶段临床试验中取得积极结果。专家认为，这是治疗此类癌症的一项“重大突破”。这款名为“intismeran autogene”的新疗法采用mRNA技术。该技术此前已被用于研制新冠疫苗。研究人员多年来一直尝试开发基于mRNA技术的癌症疗法，此次三期临床试验取得积极结果尚属首次。","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820101753777.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820101753777.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20101758183255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1617","LNGR","BK1583","BK1141","BK1574","MEDX","06978","BK1161","02228","159992","IBBQ","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660727594","title":"港股创新药板块走高，云顶新耀现涨48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660727594","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660727594?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:45","pubTimestamp":1787190347,"startTime":"0","endTime":"0","summary":"8月20日，港股创新药板块走高，云顶新耀现涨48%，中国生物制药涨17%，石药集团涨超13%，复星医药涨7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202608203847405942.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202608203847405942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","01952","IBBQ","KCAI","BK1583","159992","MEDX","BK1574","VXUS","BK1161","06978","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114428700","title":"异动解读｜云顶新耀盘中上涨47.06%，mRNA赛道催化叠加中期业绩大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1114428700","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114428700?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:43","pubTimestamp":1787190204,"startTime":"0","endTime":"0","summary":"8月20日，云顶新耀盘中上涨47.06%，报35.14港元，成交额9.8亿港元。消息面上，8月19日莫德纳与默沙东宣布其合作的mRNA个性化癌症疫苗首个III期临床试验取得初步阳性结果，Moderna隔夜股价飙涨近177%，mRNA赛道迎来价值重估。同日，云顶新耀公布中期业绩，上半年收益11.48亿元，同比增长157.29%，毛利同比增长166.98%，亏损同比大幅收窄97.62%至594.4万元，接近盈亏平衡。毛利率提升至69.6%。双重利好共振推动股价大幅走高，同板块康希诺生物同日涨43.87%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"云顶新耀盘中上涨47.06%，mRNA赛道催化叠加中期业绩大超预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660455472","title":"云顶新耀盘初大涨逾89% 上半年收入11.48亿元同比增长157%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660455472","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660455472?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:41","pubTimestamp":1787190060,"startTime":"0","endTime":"0","summary":"模拟交易客户端云顶新耀早盘一度高开逾89%，截至发稿，股价上涨54.62%，现报36.80港元，成交额7.59亿港元。报告显示，公司上半年实现总收入达人民币11.48亿元，同比增长157%；毛利率73.7%；通过持续优化资源配置和提升运营效率，公司盈利能力显著改善，Non-IFRS净利润9，723万元，常规经营性利润4，812万元，同比实现扭亏为盈。截至上半年末，现金余额达18.59亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-20/doc-ininxkry2176404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124447538","title":"港股生物科技股大涨，思路迪医药股份涨超80%，云顶新耀涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124447538","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124447538?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:30","pubTimestamp":1787189405,"startTime":"0","endTime":"0","summary":"8月20日，港股$生物(000504)$科技股大涨，$思路迪医药股份(01244)$涨超80%，$云顶新耀(01952)$涨超60%，$康希诺生物(06185)$涨超50%，$艾美疫苗(06660)$涨超45%，$剂泰科技-P(07666)$涨超25%，$科济药业-B(02171)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03069","02171","BK1161","06660","03034","09086","09834","BK1583","VXUS","07266","07568","01244","03455","BK1574","06185","XLK","KCAI","BK1585","03086","BK1147","BK1191","01952","BK4588","02834","VGT","07261","TTTN","07522","07666","BK4585","BK1515","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660047254","title":"港股异动 | 云顶新耀(01952)高开近15% Moderna癌症疫苗突破点燃mRNA赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2660047254","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660047254?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:25","pubTimestamp":1787189128,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀高开近15%，截至发稿，涨14.96%，报27.36港元，成交额1255.82万港元。消息面上，8月19日，莫德纳与默沙东宣布，双方合作的mRNA个性化癌症疫苗intismeran autogene首个III期临床试验取得初步阳性结果。受此催化，Moderna隔夜股价飙涨近177%。此次黑色素瘤三期试验的成功，被市场视为检验mRNA个性化癌症疫苗技术路径可行性的关键节点，赛道有望迎来价值重估契机。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","159646","BK4588","BK1583","BK1161","01952","BK1574","KCAI","VXUS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.1198},{"period":"1month","weight":0.2961},{"period":"3month","weight":0.1293},{"period":"6month","weight":-0.1159},{"period":"1year","weight":-0.4925},{"period":"ytd","weight":-0.1217}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.224714},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.090363},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.046758},{"month":9,"riseRate":0.5,"avgChangeRate":0.038469},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}